
SLRN
Healthcare · Biotechnology · $229.2M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2025
EPS trend, 90 days to now · -51.4% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 12, 2025 | After the close | -0.95 | -0.55 | +42.1% |
| Mar 27, 2025 | Time not confirmed | -0.67 | -0.79 | -17.9% |
| Nov 8, 2024 | After the close | -0.80 | -0.49 | +38.8% |
| Aug 14, 2024 | Time not confirmed | -0.66 | -0.86 | -29.7% |
| May 14, 2024 | After the close | -0.98 | -0.36 | +63.3% |
| Mar 28, 2024 | After the close | -0.99 | -0.97 | +2.0% |
| Nov 7, 2023 | After the close | -0.50 | -0.87 | -74.0% |
| Aug 14, 2023 | After the close | -0.76 | -0.40 | +47.4% |
| Jun 15, 2023 | After the close | -10.89 | -2.11 | +80.6% |
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and…